Cargando…
An Update on Current Therapeutic Drugs Treating COVID-19
The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeut...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211915/ https://www.ncbi.nlm.nih.gov/pubmed/32395418 http://dx.doi.org/10.1007/s40495-020-00216-7 |
_version_ | 1783531538984468480 |
---|---|
author | Wu, Renyi Wang, Lujing Kuo, Hsiao-Chen Dina Shannar, Ahmad Peter, Rebecca Chou, Pochung Jordan Li, Shanyi Hudlikar, Rasika Liu, Xia Liu, Zhigang Poiani, George J. Amorosa, Louis Brunetti, Luigi Kong, Ah-Ng |
author_facet | Wu, Renyi Wang, Lujing Kuo, Hsiao-Chen Dina Shannar, Ahmad Peter, Rebecca Chou, Pochung Jordan Li, Shanyi Hudlikar, Rasika Liu, Xia Liu, Zhigang Poiani, George J. Amorosa, Louis Brunetti, Luigi Kong, Ah-Ng |
author_sort | Wu, Renyi |
collection | PubMed |
description | The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control measures and supportive care including supplemental oxygen and mechanical ventilatory support. Evolving research and clinical data regarding the virologic SARS-CoV-2 suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others. We hope that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2. |
format | Online Article Text |
id | pubmed-7211915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-72119152020-05-11 An Update on Current Therapeutic Drugs Treating COVID-19 Wu, Renyi Wang, Lujing Kuo, Hsiao-Chen Dina Shannar, Ahmad Peter, Rebecca Chou, Pochung Jordan Li, Shanyi Hudlikar, Rasika Liu, Xia Liu, Zhigang Poiani, George J. Amorosa, Louis Brunetti, Luigi Kong, Ah-Ng Curr Pharmacol Rep Hot Topic The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control measures and supportive care including supplemental oxygen and mechanical ventilatory support. Evolving research and clinical data regarding the virologic SARS-CoV-2 suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others. We hope that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2. Springer International Publishing 2020-05-11 2020 /pmc/articles/PMC7211915/ /pubmed/32395418 http://dx.doi.org/10.1007/s40495-020-00216-7 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Hot Topic Wu, Renyi Wang, Lujing Kuo, Hsiao-Chen Dina Shannar, Ahmad Peter, Rebecca Chou, Pochung Jordan Li, Shanyi Hudlikar, Rasika Liu, Xia Liu, Zhigang Poiani, George J. Amorosa, Louis Brunetti, Luigi Kong, Ah-Ng An Update on Current Therapeutic Drugs Treating COVID-19 |
title | An Update on Current Therapeutic Drugs Treating COVID-19 |
title_full | An Update on Current Therapeutic Drugs Treating COVID-19 |
title_fullStr | An Update on Current Therapeutic Drugs Treating COVID-19 |
title_full_unstemmed | An Update on Current Therapeutic Drugs Treating COVID-19 |
title_short | An Update on Current Therapeutic Drugs Treating COVID-19 |
title_sort | update on current therapeutic drugs treating covid-19 |
topic | Hot Topic |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211915/ https://www.ncbi.nlm.nih.gov/pubmed/32395418 http://dx.doi.org/10.1007/s40495-020-00216-7 |
work_keys_str_mv | AT wurenyi anupdateoncurrenttherapeuticdrugstreatingcovid19 AT wanglujing anupdateoncurrenttherapeuticdrugstreatingcovid19 AT kuohsiaochendina anupdateoncurrenttherapeuticdrugstreatingcovid19 AT shannarahmad anupdateoncurrenttherapeuticdrugstreatingcovid19 AT peterrebecca anupdateoncurrenttherapeuticdrugstreatingcovid19 AT choupochungjordan anupdateoncurrenttherapeuticdrugstreatingcovid19 AT lishanyi anupdateoncurrenttherapeuticdrugstreatingcovid19 AT hudlikarrasika anupdateoncurrenttherapeuticdrugstreatingcovid19 AT liuxia anupdateoncurrenttherapeuticdrugstreatingcovid19 AT liuzhigang anupdateoncurrenttherapeuticdrugstreatingcovid19 AT poianigeorgej anupdateoncurrenttherapeuticdrugstreatingcovid19 AT amorosalouis anupdateoncurrenttherapeuticdrugstreatingcovid19 AT brunettiluigi anupdateoncurrenttherapeuticdrugstreatingcovid19 AT kongahng anupdateoncurrenttherapeuticdrugstreatingcovid19 AT wurenyi updateoncurrenttherapeuticdrugstreatingcovid19 AT wanglujing updateoncurrenttherapeuticdrugstreatingcovid19 AT kuohsiaochendina updateoncurrenttherapeuticdrugstreatingcovid19 AT shannarahmad updateoncurrenttherapeuticdrugstreatingcovid19 AT peterrebecca updateoncurrenttherapeuticdrugstreatingcovid19 AT choupochungjordan updateoncurrenttherapeuticdrugstreatingcovid19 AT lishanyi updateoncurrenttherapeuticdrugstreatingcovid19 AT hudlikarrasika updateoncurrenttherapeuticdrugstreatingcovid19 AT liuxia updateoncurrenttherapeuticdrugstreatingcovid19 AT liuzhigang updateoncurrenttherapeuticdrugstreatingcovid19 AT poianigeorgej updateoncurrenttherapeuticdrugstreatingcovid19 AT amorosalouis updateoncurrenttherapeuticdrugstreatingcovid19 AT brunettiluigi updateoncurrenttherapeuticdrugstreatingcovid19 AT kongahng updateoncurrenttherapeuticdrugstreatingcovid19 |